Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RZ 629

Next Previous
Drug Profile

RZ 629

Alternative Names: RZ-629

Latest Information Update: 13 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rezubio Pharmaceuticals
  • Class Antihyperglycaemics; Obesity therapies; Small molecules
  • Mechanism of Action FFAR1 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 13 Jan 2026 Phase-I clinical trials in Obesity (PO), prior to January 2025 (Rezubio Pharmaceuticals pipeline, January 2025)
  • 19 Dec 2025 RezuBio plans a phase II trial for Obesity and Diabetes mellitus
  • 20 Jul 2024 RezuBio files patent application entitled "Antidiabetic compounds and compositions" worldwide

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top